Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy
Zofia Wotschofsky(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Glen Kristiansen(University Hospital Bonn), I. Melcher(Charité - Universitätsmedizin Berlin), Andreas Erbersdobler(Universitätsmedizin Rostock), Ergin Kilic(Istanbul Technical University), Monika Jung(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Jonas Busch(Charité - Universitätsmedizin Berlin), K.-D. Schaser(Charité - Universitätsmedizin Berlin), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin)
Cited by 66
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705